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ABSTRACT
Objective: Determinants of the increased risk of
diffuse large B-cell lymphoma (DLBCL) in SLE are
unclear. Using data from a recent lymphoma genome-
wide association study (GWAS), we assessed whether
certain lupus-related single nucleotide polymorphisms
(SNPs) were also associated with DLBCL.
Methods: GWAS data on European Caucasians from
the International Lymphoma Epidemiology Consortium
(InterLymph) provided a total of 3857 DLBCL cases
and 7666 general-population controls. Data were
pooled in a random-effects meta-analysis.
Results: Among the 28 SLE-related SNPs
investigated, the two most convincingly associated with
risk of DLBCL included the CD40 SLE risk allele
rs4810485 on chromosome 20q13 (OR per risk
allele=1.09, 95% CI 1.02 to 1.16, p=0.0134), and the
HLA SLE risk allele rs1270942 on chromosome
6p21.33 (OR per risk allele=1.17, 95% CI 1.01 to 1.36,
p=0.0362). Of additional possible interest were
rs2205960 and rs12537284. The rs2205960 SNP,
related to a cytokine of the tumour necrosis factor
superfamily TNFSF4, was associated with an OR per
risk allele of 1.07, 95% CI 1.00 to 1.16, p=0.0549.
The OR for the rs12537284 (chromosome 7q32, IRF5
gene) risk allele was 1.08, 95% CI 0.99 to 1.18,
p=0.0765.
Conclusions: These data suggest several plausible
genetic links between DLBCL and SLE.
Several recent studies have highlighted an
increased risk of haematological malignan-
cies, particularly non-Hodgkin’s lymphoma
(NHL), in patients with SLE.1 2 The determi-
nants of the increased risk of NHL in SLE
are unclear. The most common type of NHL
in SLE (as in the general population) is the
diffuse large B-cell lymphoma (DLBCL)
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subtype. Using data from a recent NHL genome-wide
association study (GWAS),3 our objective was to deter-
mine if certain SLE-related single nucleotide poly-
morphisms (SNPs) were also associated with the risk of
DLBCL.
We focused on 28 SNPs independently associated with
SLE in European Caucasians.4 All of these SNPs have
been strongly associated with lupus risk, with a p value
of 1×10−7 or stronger. Our hypothesis was that these
SNPs would also be associated with DLBCL risk.
METHODS
GWAS data on European Caucasians from the
International Lymphoma Epidemiology Consortium
(InterLymph http://www.epi.grants.cancer.gov/Inter
Lymph) studies and participating cohort studies were
based on a total of 3857 DLBCL cases and 7666 controls.
Each participating study’s investigators obtained approval
from human subjects review committees and informed
consent from all participants. De-identiﬁed data were pro-
vided by the InterLymph Data Coordinating Center
(Mayo Clinic, Rochester, Minnesota, USA).
For each SLE-related SNP, the ORs and 95% CIs were
computed using a log-additive logistic regression model.
Results from three previously conducted DLBCL GWAS
studies were pooled in a random-effects meta-analysis.
With 28 comparisons, an α of 0.05 would correspond to
a Bonferroni-corrected p value of 0.0018.
RESULTS
Among the 28 SLE-related SNPs investigated (table 1),
the two most convincingly associated with risk of DLBCL
when correcting for multiple comparisons included the
CD40 SLE risk allele rs4810485 on chromosome 20q13
(OR per risk allele=1.09, 95% CI 1.02 to 1.16, p=0.0134)
and the HLA SLE risk allele rs1270942 on chromosome
6p21.33 (OR per risk allele 1.17, 95% CI 1.01 to 1.36,
p=0.0362). Two other SNPs were of additional possible
interest in DLBCL, with 95% CIs that just barely
included the null value. The rs2205960 SNP, related to a
cytokine of the tumour necrosis factor superfamily
TNFSF4, was associated with an OR per risk allele of
1.07, 95% CI 1.00 to 1.16, p=0.0549. The OR for the
SLE interferon regulatory factor (IRF5) risk allele
Table 1 SLE-related single nucleotide polymorphisms (SNPs) and ORs for diffuse large B-cell lymphoma (DLBCL) in
European Caucasians in InterLymph data
Gene Chromosome SNP
Allele*
DLBCL SLE
ref.
DLBCL
OR DLBCL 95% CI
p Value*
DLBCL
CD40 20 rs4810485 T T C 1.088 (1.017 to 1.162) 0.013355
HLA 6 rs1270942 G G A 1.171 (1.010 to 1.357) 0.036172
TNFSF4 1 rs2205960 A A G 1.074 (0.998 to 1.156) 0.054899
IRF5 7 rs12537284 A A G 1.081 (0.992 to 1.179) 0.076450
ILI10 1 rs3024505 A A G 1.102 (0.898 to 1.353) 0.352319
BANK1 4 rs10516487 A A G 1.035 (0.969 to 1.106) 0.303231
Mir146a 5 rs57095329 G G A 1.020 (0.756 to 1.377) 0.896089
ITGAM 16 rs9888739 T T C 1.008 (0.923 to 1.102) 0.851519
IFIH1 2 rs1990760 T T C 1.037 (0.978 to 1.101) 0.223359
TNFAIP3 6 rs7749323 A A G 1.053 (0.884 to 1.253) 0.564425
NCF2 1 rs17849502 T G G 1.050 (0.892 to 1.236) 0.554699
STAT4 2 rs7582694 G C C 1.110 (0.977 to 1.260) 0.108048
PTPN22 1 rs2476601 G A A 1.043 (0.937 to 1.161 0.441704
TYK2 19 rs280519 G A A 1.016 (0.959 to 1.077) 0.582604
PHRF1/IRF7/
KIAA1542
11 rs4963128 C T T 1.018 (0.956 to 1.085) 0.570646
CD44 11 rs507230 A G G 1.000 (0.941 to 1.062) 0.987988
XKR6 8 rs6985109 A G G 1.040 (0.981 to 1.103) 0.187826
JAZF1 7 rs849142 C T T 1.012 (0.903 to 1.134) 0.836267
UBE2L3 22 rs463426 C G T 1.060 (0.938 to 1.197) 0.349982
BLK 8 rs7812879 C A T 1.058 (0.956 to 1.172) 0.276113
FCGR2A, FCGR3B 1 rs1801274 G T A 1.023 (0.913 to 1.147) 0.693045
IKZF1 7 rs4917014 G C T 1.020 (0.916 to 1.138) 0.710394
LYN 8 rs7829816 G C A 1.031 (0.959 to 1.107) 0.411987
TNIP1 5 rs10036748 T G C 1.015 (0.950 to 1.085) 0.652213
IRF8 16 rs2280381 T A C 1.096 (0.933 to 1.287) 0.265341
ATG5 6 rs548234 T G C 1.033 (0.936 to 1.140) 0.518828
PXK 3 rs6445975 T C G 1.011 (0.945 to 1.083) 0.743076
IL2/IL21 4 rs907715 T G C 1.033 (0.967 to 1.104) 0.339144
*With 28 comparisons, an α of 0.05 would correspond to a Bonferroni-corrected p value of 0.0018.
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rs12537284 (chromosome 7q32, gene) was 1.08, 95% CI
0.99 to 1.18, p=0.0765. A table presenting the study-
speciﬁc contributions to the meta-analysis is provided in
the online supplemental material.
DISCUSSION
Multiple studies have highlighted an increased risk of
haematological malignancies, particularly NHL, in
patients with SLE. To date, the reason for this excess risk
has remained elusive. Recently, advances have been
made in our understanding of lymphoma risk in other
autoimmune rheumatic diseases, such as primary
Sjögren’s syndrome, where the majority of patients with
mucosa-associated lymphoid tissue (MALT) lymphoma
have either germline polymorphisms of TNFAIP3 related
to the A20 protein important in nuclear factor κB activa-
tion or somatic alterations of the gene within the lymph-
oma tissue.5 In their assessment of genetic risk overlap
between rheumatoid arthritis (RA) and haematological
cancers, Okada et al6 found that polymorphisms of
TNFAIP3 were common to both RA and Hodgkin’s
lymphoma. Our analyses did not conﬁrm a strong rela-
tionship with the lupus-related TNFAIP3 SNP rs7749323
speciﬁcally for DLBCL, but this may be a power issue, or
may reﬂect the importance of different pathways for dif-
ferent haematological risk proﬁles across different auto-
immune rheumatic diseases. Of note, our analyses were
done in Caucasian populations; several non-Caucasian
race/ethnic groups (eg, blacks, Asians) may have differ-
ent genetic risk proﬁles and clinical presentations, thus
future analyses could consider these populations as well.
We have previously shown that the increased risk of
lymphoma in SLE is similar across white, black and Asian
patients.7 In addition, it may be that speciﬁc genetic risk
factors for different clinical SLE manifestations may
drive some of the risk of lymphoma, although we were
unable to investigate that hypothesis here.
Existing data do suggest that some human leukocyte
antigen (HLA) polymorphisms inﬂuence risk of DLBCL.8
In recent DLBCL GWAS analyses, HLA-B 08-01 reached
genome-wide signiﬁcance.4 In SLE, the strongest associ-
ation in HLA is for the Class II allele DRB1*0301. This
allele is in strong linkage disequilibrium with
HLA-B*0801 in Caucasians so we are likely tagging the
same HLA effect.9 CD40, a member of the tumour necro-
sis superfamily, plays a central role in regulating immune
cells; CD40 is expressed on several B-cell neoplasms
including DLBCL. Data have suggested a possible role for
functional polymorphisms (speciﬁcally, C vs T, rs1883832)
in the TNFRSF5 gene encoding CD40 in lymphomas ori-
ginating within the germinal centre (both DLBCL and
follicular).10 Tumour necrosis factor ligand superfamily
involvement has been suggested in the pathology of malig-
nant lymphomas.11 Furthermore, in human NHL B-cell
lines, IRF5 initiates a regulatory cascade by inducing the
transcription factor activator protein 1 (AP-1) and cooper-
ating with nuclear factor kappa B (NF-κB), which appears
to represent a potentially important tumour promoting
role of IRF5 in lymphoma.12
Not all of the excess risk of haematological malignan-
cies in SLE is necessarily due to genetic factors; expo-
sures within the environment may also be at play.
However, in the InterLymph Subtypes pooling project,
autoimmune diseases as a risk for lymphoma appeared
to be independent of other potentially shared environ-
mental risk factors (body mass index, sun, alcohol, occu-
pation, etc).13 In the work of Ekström Smedby et al, SLE
was associated with a 2.7-fold increase in risk of NHL
risk overall; this was highest among patients with SLE of
short duration (2–5 years), but a near twofold increase
was also observed with more than 10 years of disease.
Use of corticosteroid and immunosuppressive drugs cat-
egorically was not clearly linked to higher or lower risk,
but analyses were not detailed.2 Two very comprehensive
case-control studies of SLE-related medications have sug-
gested a link between cyclophosphamide (used intraven-
ously in severe or resistant forms of SLE, especially
nephritis) and haematological malignancies in general14
(and speciﬁcally, in lymphoma15). Fortunately, lymph-
oma after cyclophosphamide SLE treatment is a rela-
tively uncommon outcome. Future studies of
interactions between genetic factors and drug exposures
may be warranted.
In conclusion, we studied a large GWAS datasets and
found several plausible pathways linking DLBCL and
SLE. Given that cyclophosphamide exposure in SLE is
also associated with DLBCL risk, future studies might be
able to explore whether these genetic risk factors may
aid in risk stratiﬁcation and decision-making when cyclo-
phosphamide treatment is being considered for severe
forms of SLE.
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